Skip to main content
. Author manuscript; available in PMC: 2011 May 4.
Published in final edited form as: Mol Cancer Res. 2010 May 4;8(5):729–738. doi: 10.1158/1541-7786.MCR-10-0022

Figure 4.

Figure 4

Bortezomib causes an increase in the surface expression of some death receptors and cFLIPs in some RCC lines. (a) Death receptor expression on tumor cell lines was analyzed after overnight treatment with 20nM bortezomib or media alone by flow cytometry using anti-TRAIL Receptor-1 to 4 Flow Cytometry Set (Axxora). (b) DISC protein expression was measured by western blotting of cell lysates. (c) MTS assay; Cells were treated with TRAIL for 90 minutes, and then washed three times with media to remove unbound TRAIL. Media was replaced in wells and bortezomib was added for an overnight treatment. For the control plate cells were washed with media then TRAIL and/or bortezomib were added for the overnight incubation.